Obesity Eli Lilly - Search News

Zepbound, Lilly and Mounjaro

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.

Barron's on MSN · 3d

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello

Zacks.com on MSN · 2d

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

Leerink keeps Eli Lilly stock outperform

The Motley Fool on MSN · 18h

Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $8

Money Morning · 4h

Eli Lilly Faces ‘Death Cross’ Selloff: This is the Stock's Next Target Price...

Shares of Eli Lilly were already in an intermediate-term decline before the announcement. The stock has dropped 25% from its 2024 highs as investors have been unimpressed with Eli Lilly’s drug pipeline and management.

Investing.com on MSN · 11h

Leerink keeps Eli Lilly stock outperform on revenue growth

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently valued at $672.

3don MSN

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

STAT2d

Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

pharmaphorum2d

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

2don MSN

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

3don MSN

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

조선일보2d

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...

The Keene Sentinel7h

Alzheimer’s drugs eyed as next big obesity-like opportunity

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

BioSpace3d

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

9don MSN

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Eli Lilly price target lowered to $970 from $1,050 at Berenberg

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

13h

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results